Replies to post #53588 on Anavex Life Sciences Corp (AVXL)

[rnoutlaw21]

Are you talking about part A? I don't care about the daily, weekly, or even monthly pps movements. I am INVESTED for the long haul. Either I will lose my investment or win BIG. The upside potential here is well worth the risk IMO.

[XenaLives]

The market doesn't give a rip about AVXL fundamentals, otherwise we'd be trading at $10.

The market is a criminal organization designed to steal from the public and funnel money to the 1%ers.

AVXL current action is a function of the market, no more, no less.

[blu_1]

The market is sophisticated enough and doesn't track the science and trial closely enough to weigh their decision based on something like a hunch that another extension hasn't been granted. That hasn't even crossed their minds. They don't know jack about the trial or its history, not like some of us do that track this beast day in day out and read all the PR's and science articles.

[blu_1]

I track this stock as close as anybody everyday and I never thought, "Gee, if Missling doesn't reveal that the trial has been extended beyond 52 weeks that is a bad sign and maybe I should sell." That thought never even entered my mind. And I doubt it even entered Missling's that he should comment on that b/c if he doesn't the market will jump to conclusions. I just don't think that has anything to do with the PPS or the thought process of people trading this stock.

[williamssc]

I look at it like this Frrol. In mid-November Anavex announced under FDA Guidance they were moving ahead with a larger Phase2/3 trial. Since the announcement was in November the first patients would have been 11months into dosing so with them proceeding shows me they were still seeing drug efficacy and not a relapse in the long term.

[TrueTrades]

The only interim 12-week data presented on Nov 5 was an average +3.21 point increase in the ADSC-ADL score for 14 patients. The rest of the 5-week results were for the full 30pt cohort and revealed an average increase in the MMSE by +1.5 points.

What if the avg increase for the group is +4pt on the MMSE and +7pt on ADSC-ADL after 12 weeks? Placebo effect? The 5 week Cogstate results showed significant improvement in areas where high doses of Donepezil were effective over the 12-week AIBL-ROCS study period, confirming A2-73's synergistic affect and allowing smaller doses of the side-effect-heavy Donepezil. Neuronetrix has a wealth of data to support the use of it's COGNISON system as an FDA-approved EEG/ERP measuring tool, and the PLUS combo showed a dramatic ability to nearly normalize P300 waves in subjects. This will be tracked very closely with the other test data as P300 structure becomes more accepted in the early detection and monitoring of CNSDs.

There is no MMSE data in the interim 12-week data release, which was done on Nov 5. And this is what the market is wondering about. And they are awaiting the full results, and whether there was another extension requested and granted.

No one but you is wondering about another extension of the P2aB. A P2/3 has been officially announced as in the works. The P2a participants continue the therapy and supervision and the onus moves to the next phase. Hopefully to be terminated early for efficacy.

AVXL current action is a function of the market, no more, no less. -XenaLives

Precisely. The reality is all the aspects of drug development, from what the insiders did when they were 10 to frivolous lawsuits to meetings with the FDA special board are part of the game. The statistics say that 77% of drugs that reach phase 3 testing are approved and the FDA desperately wants to see more effective CNS therapies introduced. The company and CEO have performed impeccably in their development of the business model in this market...which is down 2% again today. 1+1=2

Family stink bids filled. Time for spaghetti lunch...hit-it, tom! ;-)
§
ed- I see you beat me to it...but no pasta? :-)